Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus
View/ Open
Author
Becker, Stephen C.
Roach, Dwayne R.
Chauhan, Vinita S.
Shen, Yang
Foster-Frey, Juli
Powell, Anne M.
Bauchan, Gary
Lease, Richard A.
Mohammadi, Homan
Harty, William J.
Simmons, Chad
Schmelcher, Mathias
Camp, Mary
Dong, Shengli
Baker, John R.
Sheen, Tamsin R.
Doran, Kelly S.
Pritchard, David G.
Almeida, Raul A.
Nelson, Daniel C.
Marriott, Ian
Donovan, David M.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/srep25063Metadata
Show full item recordCitation
Becker, S. C., D. R. Roach, V. S. Chauhan, Y. Shen, J. Foster-Frey, A. M. Powell, G. Bauchan, et al. 2016. “Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus.” Scientific Reports 6 (1): 25063. doi:10.1038/srep25063. http://dx.doi.org/10.1038/srep25063.Abstract
Multi-drug resistant bacteria are a persistent problem in modern health care, food safety and animal health. There is a need for new antimicrobials to replace over used conventional antibiotics. Here we describe engineered triple-acting staphylolytic peptidoglycan hydrolases wherein three unique antimicrobial activities from two parental proteins are combined into a single fusion protein. This effectively reduces the incidence of resistant strain development. The fusion protein reduced colonization by Staphylococcus aureus in a rat nasal colonization model, surpassing the efficacy of either parental protein. Modification of a triple-acting lytic construct with a protein transduction domain significantly enhanced both biofilm eradication and the ability to kill intracellular S. aureus as demonstrated in cultured mammary epithelial cells and in a mouse model of staphylococcal mastitis. Interestingly, the protein transduction domain was not necessary for reducing the intracellular pathogens in cultured osteoblasts or in two mouse models of osteomyelitis, highlighting the vagaries of exactly how protein transduction domains facilitate protein uptake. Bacterial cell wall degrading enzyme antimicrobials can be engineered to enhance their value as potent therapeutics.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848530/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320316
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)